Skip to content
Medical Health Aged Care

Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

Morinaga Milk Industry Co., Ltd. 3 mins read
TOKYO--BUSINESS WIRE--

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-63 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and children foods (under the age of three) on 25 July, 2024. This approval marks a significant milestone for the company, making it the only Japanese firm to have three bifidobacteria strains registered for use in China’s infant and toddler food market1.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808893280/en/

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

*1 Source: Public announcement published on the website of the China National Center for Food Safety Risk Assessment (August 5, 2024)

The newly registered Bifidobacterium infantis M-63 joins Morinaga Milk’s other approved strains, Bifidobacterium breve M-16V and Bifidobacterium longum BB536. All three strains are now permitted for use in foods for children under three years old in China, meeting the country's stringent nutritional and safety standards.

Expanding Global Presence

This approval aligns with Morinaga Milk’s 10-year vision to become a globally recognized company with a significant international presence. As part of this vision, the company aims to achieve a Global Business sales ratio of 15% or more by the fiscal year ending in March 2029. The approval of Bifidobacterium infantis M-63 represents a strategic step towards this goal, allowing Morinaga Milk to strengthen its bacteria business in the Chinese market, which accounts for more than 40% of the global formula milk market and is the second-largest supplement market worldwide2.

*2 Source: Survey by Euromonitor International (May 2024), based on retail sales prices

Health Benefits of Bifidobacterium infantis M-63

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. With China's recent approval of HMO use in formula milk in October 20233, the combination of Bifidobacterium infantis M-63 and HMO is expected to support the growth of beneficial intestinal bacteria, enhancing the development and health of infants and toddlers4.

*3 Source: National Health Commission of the People’s Republic of China, No. 8, 2023 (Sept. 22, 2023)
*4 Source: Mintel, “HMOs approval in China infant formula is a game changer” (Jan. 2024)

Probiotics strain of bifidobacteria registered as New Food Ingredients in China

Strain

Registration date

Bifidobacterium breve M-16V

Registered name: 短双歧杆菌 M-16V

2016

Bifidobacterium longum subsp. longum BB536

Registered name: 长双歧杆菌长亚种 BB536

2022

Bifidobacterium longum subsp. infantis M-63

Registered name: 长双歧杆菌婴儿亚种M-63

2024

* All three strains are approved for use in foods for infants and toddlers under the age of three.

Commitment to Quality and Research

Morinaga Milk has been at the forefront of bifidobacteria research since discovering Bifidobacterium longum BB536 in 1969. The company leads globally in the number of clinical research papers on bifidobacteria, underlining its commitment to advancing scientific understanding and improving public health.

Future Prospects

The registration of Bifidobacterium infantis M-63 paves the way for its use in a wide range of products. Morinaga Milk plans to leverage this approval to expand collaborations with major formula milk manufacturers and promote supplements and other related products in China and globally. By providing accurate information on the benefits of Bifidobacterium infantis M-63 to consumers and partners, Morinaga Milk aims to enhance the health and nutrition of people worldwide.

About Morinaga Milk Industry

Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.


Contact details:

Morinaga Milk Industry Co., Ltd. 
Mitsunori Watanabe / Kazuaki Kajikawa, Investor& Public Relations Department
Junichi Minami / Chyn Boon Wong, International Division
E-mail: interntl-pr@morinagamilk.co.jp
Morinaga Milk website: https://www.morinagamilk.co.jp/english/

Media

More from this category

  • Medical Health Aged Care
  • 04/12/2024
  • 12:05
Independent Health and Aged Care Pricing authority

Ongoing refinement and extensive consultation reflected in new pricing framework for Australian public hospitals

Ongoing refinement and extensive consultation reflected in new pricing framework for Australian public hospitals The Independent Health and Aged Care Pricing Authority (IHACPA) today released thePricing Framework for Australian Public Hospital Services 2025–26 following public consultation. The annually updated pricing framework outlines the policy and evidence used to inform development of the National Efficient Price (NEP) Determination and the National Efficient Cost (NEC) Determination for 2025–26. The determinations are used to calculate Australian Government funding for public hospital services for the 2025–26 financial year, and will be published in March 2025. IHACPA conducted public consultation on the policy decisions outlined…

  • Medical Health Aged Care
  • 04/12/2024
  • 10:30
Royal Australian College of GPs

Strengthening Australia’s GP workforce

The Royal Australian College of GPs (RACGP) is introducing key enhancements to GP training to secure the future of Australia’s general practice workforce. From next year, the Australian General Practice Training program (AGPT) and Fellowship Support Program (FSP) will see a number of improvements for enhancing training outcomes, including: simplifying the AGPT application processes by removing referee requirements, and introducing a single online national entry assessment that can be sat remotely cutting AGPT red tape, including removing the need to have an active permanent residence application at the time of applying to ensure a fairer selection process while maintaining long-term…

  • Insurance, Medical Health Aged Care
  • 04/12/2024
  • 09:16
4 December, 2024

Aussies rush to finish the year on a healthy note

With the end of 2024 fast approaching, Aussies are rushing to book in medical appointments before the silly season and make the most out of their Extras with optical, dental, myotherapy and physiotherapy appointments surging in last-minute bookings. According to the Bupa Pulse Check, a national survey of 2,000 Aussies, more than a third of people are struggling to maintain their health routines due to time or work commitments with 45 per cent of parents mentioning cost as a barrier. Bupa Health Services Clinical Director Dr Tony MacDermott said busy Australians were looking to get more value out of their…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.